A Phase 1/2 Open-label, Multi-center, Dose-escalation Study of Safety, Tolerability, Pharmacokinetics, Dosimetry, and Response to Repeat Dosing of 177Lu-PSMA-R2 Radio-ligand Therapy in Patients With Prostate Specific Membrane Antigen (PSMA) Positive (68Ga-PSMA-R2) Progressive Metastatic Castration-resistant Prostate Cancer, Following Previous Systemic Treatment
Latest Information Update: 11 Oct 2023
At a glance
- Drugs Lutetium 177 PSMA R2 (Primary) ; Gallium 68 PSMA R2
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms PROter
- Sponsors Advanced Accelerator Applications
- 01 Jul 2022 Status changed from active, no longer recruiting to discontinued.
- 28 Oct 2021 Planned End Date changed from 1 Dec 2022 to 22 May 2026.
- 28 Oct 2021 Planned primary completion date changed from 1 Dec 2022 to 7 Jul 2022.